Lucentis (Ranibizumab)

Generic Name

Ranibizumab

Brand Names

Lucentis, Cimerli, Susvimo, Byooviz

FDA approval date: June 30, 2006

Classification: Vascular Endothelial Growth Factor Inhibitor

Form: Injection

What is Lucentis (Ranibizumab)?

CIMERLI is indicated for the treatment of patients with: CIMERLI, a vascular endothelial growth factor inhibitor, is indicated for the treatment of patients with: Neovascular Age-Related Macular Degeneration .

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

Enrollment Status: Recruiting

Publish Date: April 14, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: Neovascular age-related macular degeneration (nAMD), also known as wet AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. The purpose of this study is to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD). Surabgene Lomparvovec (ABBV-RGX-314) i...

A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS)

Who is this study for: Patients with neovascular age-related macular degeneration previously treated with intravitreal agents other than ranibizumab

Enrollment Status: Recruiting

Publish Date: April 13, 2026

Intervention Type: Device, Drug

Study Drug: Lucentis

Study Phase: Phase 4

Summary: This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

A Comparative Analysis of OCT and OCT Angiography Biomarkers and Systemic Laboratory Parameters in Patients With Diabetic Retinopathy Undergoing Treatment With Faricimab or Biosimilar Ranibizumab Following Three Loading Doses

Enrollment Status: Recruiting

Publish Date: April 09, 2026

Intervention Type: Drug

Study Phase: Not Applicable

Summary: The goal of this clinical trial is to see if treatment with faricimab or biosimilar ranibizumab leads to different early imaging changes in adults with diabetic retinopathy requiring anti-VEGF treatment and to identify OCT and OCTA biomarkers predictive of differential early treatment response between the two therapies. The main questions it aims to answer are: Which OCT and OCT angiography biomar...

View All Clinical Trials